Novo Nordisk reported DKK239.08B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Bausch Health Companies USD 4.54B 14M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Merck USD 27.73B 786M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Novo Nordisk DKK 36.54B 188.62B Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026